Amgen cholesterol drug reduces arterial plaque buildup: study
(Reuters) - Amgen Inc said on Tuesday its potent new cholesterol fighter, Repatha, met the primary and secondary goals of a study designed to show it can decrease plaque buildup in heart arteries of patients already taking widely used statin drugs, such as Lipitor.
In conclusion, our findings suggest that GGPPS provides protection against pulmonary fibrosis and the restoration of protein geranylgeranylation may benefit statin-induced lung injury. PMID: 31120854 [PubMed - as supplied by publisher]
Taking statins before or after cancer diagnosis cuts all - cause and cancer - related deaths
Conclusion: Although preliminary, the results of the present study showed that topical atorvastatin has a comparable effect to topical betamethasone and can be considered as an alternative therapeutic modality in the treatment of scalp SD. However, these results need to be confirmed in future studies while taking into consideration the improvement of topical statin formulations. PMID: 31118730 [PubMed]
ConclusionsNo evidence of an association between the use of metformin or statins and the incidence of breast cancer in women with T2D was found. Among insulin users, a slightly higher incidence of breast cancer was observed.
Combination of statins and clopidogrel is frequently administered in patients with coronary artery disease (CAD). They are mainly activated and eliminated in the liver by cytochrome P450 isoenzyme 3A4 (CYP3A4)...
The study sought to assess the impact of statin therapy on survival in patients presenting with ventricular tachyarrhythmias.
ConclusionsAlthough the intervention did not reach a reduction in cholesterol levels, it had a significant positive impact on the promotion of adequate use of clinical practice guidelines.Trial registrationThis study is registered at www.clinicaltrials.gov NCT02380911.
AbstractPurpose of ReviewAt the 2019 American College of Cardiology annual scientific sessions, major randomized clinical trials in cardiovascular disease (CVD) prevention were presented.Recent FindingsThe CLEAR Wisdom trial examined the safety and efficacy of adding bempedoic acid to maximally tolerated statin for reducing low-density lipoprotein cholesterol. Post hoc analyses from the REDUCE-IT trial evaluated the efficacy of icosapent ethyl for lowering risk of total (first time and recurrent) CVD events. A sub-analysis of ODYSSEY OUTCOMES examined the effect of alirocumab on lipoprotein(a) lowering for reducing CVD ris...
We examined the incidence rate and risk factors of osteoporotic vertebral fracture in RA patients with new-onset CVD (RA-CVD) and evaluated the effects of medications on such fracture risk.MethodsA retrospective study was conducted using a nationwide database from 2000 to 2010: 1267 RA-CVD and 1267 non-CVD patients were enrolled from 30,507 patients with newly diagnosed RA. The main outcome was the development of osteoporotic vertebral fracture. After being adjusted for age, gender, and comorbidities, the Cox proportional hazard model was used to identify independent factors contributing to osteoporotic vertebral fracture....
We describe two cases of colchicine myopathy which occurred with co-administration of rosuvastatin. From one case, we present the first published data on muscle MRI in this condition. We additionally present an analysis of four genetic polymorphisms in ABCB1 and transcript levels in muscle tissue, and demonstrate the descriptive finding of reduced ABCB1 transcript levels in the colchicine myopathy patients.